Crestwood Advisors Group LLC Purchases New Position in Repligen Corporation (NASDAQ:RGEN)

Crestwood Advisors Group LLC bought a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,647 shares of the biotechnology company's stock, valued at approximately $464,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in shares of Repligen during the 4th quarter worth about $29,000. Raiffeisen Bank International AG purchased a new position in Repligen in the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. purchased a new position in Repligen in the 4th quarter worth approximately $40,000. Finally, Center for Financial Planning Inc. raised its position in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RGEN. Evercore ISI cut their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Barclays began coverage on shares of Repligen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price on the stock. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Royal Bank Of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $169.92.

Repligen Stock Performance

Shares of RGEN stock traded down $0.13 during mid-day trading on Friday, reaching $121.74. The stock had a trading volume of 950,629 shares, compared to its average volume of 762,938. The firm's 50 day simple moving average is $123.68 and its 200 day simple moving average is $137.66. The firm has a market cap of $6.84 billion, a PE ratio of -270.53, a P/E/G ratio of 2.18 and a beta of 1.11. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. On average, analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.